Vol. 2 No. 8 (2022): August
Reimbursement Recommendations

Ruxolitinib (Jakavi)

  • CADTH
PDF HTML
DOI: https://doi.org/10.51731/cjht.2022.407

Published August 3, 2022

Key Messages

  • CADTH recommends that Jakavi should be reimbursed by public drug plans for the treatment of chronic graft-versus-host disease (cGvHD) if certain conditions are met.
  • Jakavi should only be covered to treat patients aged 12 years and older who did not show an adequate response to corticosteroids or other systemic treatments.
  • Jakavi should only be reimbursed if prescribed by specialists who have experience in the diagnosis and management of patients with cGvHD, and the cost of Jakavi is reduced.
PDF HTML